Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5051257 | 0.87 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL5054492 | 0.82 | CETP (0.41) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL5051203 | 0.82 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL5060618 | 0.77 | POLB (0.38) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL5051206 | 0.73 | AKR1C3 (0.39) | UTS2R | |
| SCHEMBL6037812 | 0.72 | RAB9A (0.34) | CYP2D6PIN1 | |
| SCHEMBL7609850 | 0.70 | AKR1C3 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL5057926 | 0.70 | UGT2B7 (0.43) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL7645266 | 0.69 | PIN1 (0.42) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL7616169 | 0.69 | CYP1A2 (0.43) | SLC6A2SLC6A4SLC6A3KCNH2UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-6025345-A | NOVEL PHOSPHONATE DERIVATIVES, HYDROXYPHOSPHINYL DERIVATIVES, AND PHOSPHORAMIDATE DERIVATIVES THAT INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY, | GUILFORD PHARMACEUTICALS INC. (US) | 2000-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | SLC6A2 1722/4885SLC6A4 2083/4885SLC6A3 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.